| Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and … N Pore, S Wu, N Standifer, M Jure-Kunkel, M de Los Reyes, Y Shrestha, ... Cancer discovery 11 (11), 2828-2845, 2021 | 64 | 2021 |
| A structural, functional, and computational analysis suggests pore flexibility as the base for the poor selectivity of CNG channels LMR Napolitano, I Bisha, M De March, A Marchesi, M Arcangeletti, ... Proceedings of the National Academy of Sciences 112 (27), E3619-E3628, 2015 | 35 | 2015 |
| A candidate ion-retaining state in the inward-facing conformation of sodium/galactose symporter: clues from atomistic simulations I Bisha, A Laio, A Magistrato, A Giorgetti, J Sgrignani Journal of Chemical Theory and Computation 9 (2), 1240-1246, 2013 | 26 | 2013 |
| Metadynamics Simulations Reveal a Na+ Independent Exiting Path of Galactose for the Inward-Facing Conformation of vSGLT I Bisha, A Rodriguez, A Laio, A Magistrato PLoS computational biology 10 (12), e1004017, 2014 | 25 | 2014 |
| Identification of essential amino acids for glucose transporter 5 (GLUT5)-mediated fructose transport K Ebert, M Ewers, I Bisha, S Sander, T Rasputniac, H Daniel, I Antes, ... Journal of Biological Chemistry 293 (6), 2115-2124, 2018 | 20 | 2018 |
| The molecular mechanism of secondary sodium symporters elucidated through the lens of the computational microscope I Bisha, A Magistrato RSC Advances 6 (12), 9522-9540, 2016 | 11 | 2016 |
| A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma AL Coveler, MJ Reilley, M Zalupski, T Macarulla, C Fountzilas, ... Clinical Cancer Research 30 (20), 4609-4617, 2024 | 1 | 2024 |
| Quantitative continuous scoring of PD-L1 for superior patient selection for anti-PD-L1 treatment of locally advanced or unresectable NSCLC JM Lesniak, I Bisha, S Christ, L Meinecke, T Padel, LS Monasor, ... Cancer Research 84 (6_Supplement), 7617-7617, 2024 | 1 | 2024 |
| Hardware annotation devices in computational pathology: a comparative analysis GE Alonso, T Falck, M Testori, I Bisha, Z Kokaragac, C Cotoi, S Haneder VIRCHOWS ARCHIV 485, S383-S383, 2024 | | 2024 |
| Multiplex immunofluorescence profiling of the tumor microenvironment and CD73: Activity of neoadjuvant oleclumab in patients with non-small-cell lung cancer in NeoCOAST I Bisha, TH Tan, M Weitkunat, A Andoni, I Dino, P Martin, M Saraiya, ... Cancer Research 84 (6_Supplement), 2023-2023, 2024 | | 2024 |
| EP06. 05-09 Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC S Christ, A Kapil, I Bisha, J Chan, A Andoni, C Cotoi, M Schick, G Schmidt, ... Journal of Thoracic Oncology 18 (11), S497, 2023 | | 2023 |
| P59. 15 Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)? IJ Eide, AP Dyrbekk, Å Helland, S Ekman, J Koivunen, S Cicenas, ... Journal of Thoracic Oncology 16 (10), S1154, 2021 | | 2021 |
| Atomistic Study of Structural and Functional Properties of Membrane Proteins I Bisha SISSA, 2014 | | 2014 |
| Mechanism of Ionic Permeation in the Mimics of CNG Channels: A Structural, Functional and Computational Analysis LMR Napolitano, I Bisha, M Arcangeletti, A Marchesi, M De March, ... Biophysical Journal 106 (2), 758a, 2014 | | 2014 |
| P59 PREDICTIVE TUMOR BASED ASSAYS/BIOMARKERS/PATHOLOGY-TARGETED THERAPIES BIOMARKERS IJ Eide, AP Dyrbekk, Å Helland, S Ekman, J Koivunen, S Cicenas, ... | | |
| Supplementary Figure S5 from A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal … AL Coveler, MJ Reilley, M Zalupski, T Macarulla, C Fountzilas, ... American Association for Cancer Research (AACR), 0 | | |
